A citation-based method for searching scientific literature

William B White, William L Baker. Annu Rev Med 2016
Times Cited: 19







List of co-cited articles
124 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
57

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
57

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
52

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
52

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
52

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
47

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
488
36

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
36

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
407
31

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
26

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
Kristian B Filion, Laurent Azoulay, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Nianping Hu, J Michael Paterson, Laura Targownik, Tanvir C Turin,[...]. N Engl J Med 2016
150
26

Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
236
26

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
582
26

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
Darren K McGuire, Frans Van de Werf, Paul W Armstrong, Eberhard Standl, Joerg Koglin, Jennifer B Green, M Angelyn Bethel, Jan H Cornel, Renato D Lopes, Sigrun Halvorsen,[...]. JAMA Cardiol 2016
145
26

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen,[...]. Eur Heart J 2012
380
21

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George G Sokos, Lazaros A Nikolaidis, Sunil Mankad, Dariush Elahi, Richard P Shannon. J Card Fail 2006
476
21

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
649
21




Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation.
Daisuke Shiraishi, Yukio Fujiwara, Yoshihiro Komohara, Hiroshi Mizuta, Motohiro Takeya. Biochem Biophys Res Commun 2012
87
15

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
398
15

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
734
15

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
759
15



Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure.
Mads Halbirk, Helene Nørrelund, Niels Møller, Jens Juul Holst, Ole Schmitz, Roni Nielsen, Jens Erik Nielsen-Kudsk, Søren Steen Nielsen, Torsten Toftegaard Nielsen, Hans Eiskjaer,[...]. Am J Physiol Heart Circ Physiol 2010
118
15

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, June Ye, John J V McMurray. Lancet Diabetes Endocrinol 2015
53
15

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Mohammad Hossein Noyan-Ashraf, Eric Akihiko Shikatani, Irmgard Schuiki, Ilya Mukovozov, Jun Wu, Ren-Ke Li, Allen Volchuk, Lisa Annette Robinson, Filio Billia, Daniel J Drucker,[...]. Circulation 2013
157
15


Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Ling Li, Sheyu Li, Ke Deng, Jiali Liu, Per Olav Vandvik, Pujing Zhao, Longhao Zhang, Jiantong Shen, Malgorzata M Bala, Zahra N Sohani,[...]. BMJ 2016
144
15


Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
Nikolaus Marx, Julio Rosenstock, Steven E Kahn, Bernard Zinman, John J Kastelein, John M Lachin, Mark A Espeland, Erich Bluhmki, Michaela Mattheus, Bart Ryckaert,[...]. Diab Vasc Dis Res 2015
150
15

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
G McInnes, M Evans, S Del Prato, M Stumvoll, A Schweizer, V Lukashevich, Q Shao, W Kothny. Diabetes Obes Metab 2015
60
15


Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
M Monami, S Genovese, E Mannucci. Diabetes Obes Metab 2013
149
15


Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials.
J Kongwatcharapong, P Dilokthornsakul, S Nathisuwan, A Phrommintikul, N Chaiyakunapruk. Int J Cardiol 2016
48
15

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska,[...]. Eur J Heart Fail 2016
15

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
15

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Meghan Sauvé, Kiwon Ban, M Abdul Momen, Yu-Qing Zhou, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2010
219
10

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
744
10

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
401
10

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection.
John R Ussher, Laurie L Baggio, Jonathan E Campbell, Erin E Mulvihill, Minsuk Kim, M Golam Kabir, Xiemin Cao, Benjamin M Baranek, Doris A Stoffers, Randy J Seeley,[...]. Mol Metab 2014
79
10


GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes.
Hong Gao, Xinjun Wang, Zhiguo Zhang, Yisheng Yang, Jun Yang, Xiaoying Li, Guang Ning. Endocrine 2007
55
10

Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.
Antonio Ceriello, Anna Novials, Emilio Ortega, Silvia Canivell, Lucia La Sala, Gemma Pujadas, Katherine Esposito, Dario Giugliano, Stefano Genovese. Diabetes Care 2013
115
10

Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor.
Kiwon Ban, Kyoung-Han Kim, Chan-Kyung Cho, Meghan Sauvé, Eleftherios P Diamandis, Peter H Backx, Daniel J Drucker, Mansoor Husain. Endocrinology 2010
159
10

Regulation of adipocyte formation by GLP-1/GLP-1R signaling.
Tenagne Delessa Challa, Nigel Beaton, Myrtha Arnold, Gottfried Rudofsky, Wolfgang Langhans, Christian Wolfrum. J Biol Chem 2012
76
10

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.
Juraj Koska, Michelle Sands, Camelia Burciu, Karen M D'Souza, Kalyani Raravikar, James Liu, Seth Truran, Daniel A Franco, Eric A Schwartz, Dawn C Schwenke,[...]. Diabetes 2015
72
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.